Background
Methods
Patient characteristics
Tumor volume measurement
Treatment
Follow up and statistical analysis
Results
Distribution of tumor volume by category/stage
Identification and verification of TTV cut-off point
Prognostic significance of TTV in all patients
Characteristics | TTV ≤ 28 cm3
(N = 188) | TTV > 28 cm3
(N = 267) |
P Value†
|
---|---|---|---|
Sex (%) | <0.001 | ||
Male | 127 | 220 | |
Female | 61 | 47 | |
Age (years) | 0.908 | ||
≤ 45 years | 82 | 115 | |
> 45 years | 106 | 152 | |
T-categorya (%) | <0.001 | ||
T1 | 93 | 34 | |
T2 | 31 | 28 | |
T3 | 52 | 105 | |
T4 | 12 | 100 | |
N-categorya (%) | <0.001 | ||
N0 | 43 | 15 | |
N1 | 116 | 139 | |
N2 | 26 | 93 | |
N3 | 3 | 20 | |
Stage-groupa (%) | <0.001 | ||
I | 29 | 0 | |
II | 78 | 32 | |
III | 66 | 118 | |
IVa–b | 15 | 117 | |
Chemotherapy | |||
Yes | 139 | 245 | <0.001 |
No | 49 | 22 | |
Additional boost | |||
Yes | 28 | 22 | 0.025 |
No | 160 | 245 |
Endpoint | Variable | HR | 95% CI |
P-value |
---|---|---|---|---|
FFS | TTV | 4.523 | 2.482–8.241 | <0.001 |
N stagea
| 1.567 | 1.027–2.391 | 0.037 | |
OS | Sex | 1.661 | 0.915–3.013 | 0.095 |
Chemotherapy | 1.882 | 0.986–3.592 | 0.055 | |
T stagea
| 1.763 | 1.054–2.951 | 0.031 | |
N stagea
| 1.920 | 1.254–2.939 | 0.003 | |
TTV | 3.231 | 1.776–5.878 | <0.001 | |
DMFS | N stagea
| 1.764 | 1.064–2.925 | 0.028 |
TTV | 3.749 | 1.877–7.489 | <0.001 | |
LRRFS | TTV | 3.810 | 1.679–8.645 | 0.001 |
Prognostic significance of TTV in stage III-IVb NPC
Endpoint | Variable | HR | 95% CI |
P-value |
---|---|---|---|---|
FFS | TTV | 3.362 | 1.677–6.738 | 0.001 |
OS | Sex | 1.735 | 0.906–3.321 | 0.096 |
Additional boost | 1.860 | 0.947–3.654 | 0.072 | |
Chemotherapy | 2.384 | 1.109–5.126 | 0.026 | |
N stagea
| 1.551 | 0.994–2.421 | 0.053 | |
TTV | 4.364 | 2.125–8.964 | <0.001 | |
DMFS | TTV | 2.923 | 1.323–6.459 | 0.008 |
LRRFS | TTV | 2.464 | 0.951–6.383 | 0.063 |